PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
Feature|Videos|May 23, 2025
Inside Experic: Revolutionizing CDMO & Clinical Packaging Services
Author(s)Dave Wood
Dave Wood, CEO at Experic, discusses how decades of expertise with advanced technologies helps pharmaceutical and biotech partners bring products to market faster.
Experic is a contract development and manufacturing organization (CDMO) that delivers integrated pharmaceutical solutions across the drug development lifecycle. With specialized expertise in complex formulations, including precision low-dose capsule filling and inhalation therapies, Experic supports clients from early development through global distribution. Its advanced facility and experienced team enable rapid project execution through customized manufacturing, packaging, and clinical supply services. By unifying these capabilities under one roof, Experic streamlines timelines, ensures product integrity, and accelerates time to market for both emerging biotech and large pharmaceutical companies.
Learn More About:
- Experic’s integrated CDMO capabilities and how they support end-to-end pharmaceutical development and distribution.
- The unique technologies and expertise that well positions Experic in complex drug formulation and clinical packaging.
- A unified approach to manufacturing, packaging, and logistics to reduce project timelines and ensure regulatory compliance.
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Trending on Pharmaceutical Technology
1
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
4
What the Olanzapine Depot Approval Means for CMC Teams
5